Ryan T. Sowell
Amanda L. MarzoTissues such as the lung, skin, intestinal epithelium, and reproductive tract serve as a barricade against pathogen exposure for the entire body. Specifically within the skin and mucosal tissues, a population of resident CD8 T cells plays a salient role in the protection against infection. Resident-memory CD8 T cells (TRM) are a long-lived subset of memory CD8 T cells that do not re-circulate after taking up residence in the tissues. Traditionally memory CD8 T cells were conceptually divided into two subsets central (TCM) and effector (TEM) memory where TCM preferentially localized within secondary lymphoid tissues (SLO) and TEM circulated throughout the peripheral tissues. While the concept of TCM and TEM has been considerably explored, memory CD8 T cells found within barrier tissues do not totally fit within the TCM/TEM paradigm. Through the study of circulating CD8 T cells, our understanding of memory CD8 T cells has grown tremendously in the last 25 years. We now understand that it is not sufficient to simply generate large numbers of circulating memory CD8 T cells in order to enhance protection against localized infection. Developing clinical strategies that can enhance protection against mucosal pathogens will require a clear understanding of how memory CD8 T cells are generated and maintained within barrier tissues at the sites of initial pathogen exposure. We will outline our current understanding of TRM in respect to their generation, functional importance, and how future studies must shed light on how we can exploit TRM to develop the next generation of effective vaccines.
Generation of Tissue-Resident- Memory CD8 T Cells
CD8 T cells are primed within tissue draining lymph nodes and lymphoid tissues. Once primed, CD8 T cells receive tissue-specific signals that allow them entry into tissues, which at steady-state are normally non-permissive to T cell migration (1). Upon entry into mucosal or skin tissues CD8 T cells take up residence and do not re-circulate (2, 3). For T cells to enter the small intestine the integrin α4β7 and chemokine receptor CCR9 are important (4, 5). α4β7 and CCR9 expression is induced by dendritic cell-derived signals like the vitamin A metabolite retinoic acid (6). α4β7 is transiently expressed and the timing of its expression correlates with the window of opportunity for T cell migration into the small intestine (2, 4, 5). Primed T cells that enter mucosal tissues differentiate into TRM in response to tissue-derived signals, not limited to but including TGF-β and IL-15 (5, 7). Tissue-derived signals like TGF-β and IL-15 are not uniquely confined to barrier tissues, as their availability is also important for circulating CD8 T cells. TRM originate from KLRG1− effector cells, are not terminally differentiated, however, express lower levels of CD127 and CD122 than circulating memory CD8 T cells (7, 8). While TRM share a common naïve precursor with blood and SLO memory cells they are inherently different from their circulating counterparts (9). Unlike circulating memory CD8 T cells, TRM maintain expression of CD69 and elevated levels of Granzyme B, attributes akin to effector cells (2, 10, 11). Generation of TRM is dependent on CD69 as overexpression S1pr1 or deletion of CD69 in CD8 T cells limits TRM formation (7, 12). TRM also upregulate the integrin subunit CD103 whereas circulating memory CD8 T cells remain CD103− (2, 8). A qualitative feature that distinguishes circulating TCM and TEM from TRM is that regardless of infection or anatomical location TRM share a signature of core gene transcripts (7). Within this signature are genes involved in chemotaxis, adhesion, and co-stimulation. Expression of some genes associated with circulating memory cells are decreased, e.g., Eomes, S1pr1, and Ly6C. The signaling events that regulate the transcriptional programing of TRM is unknown.
mTOR and TRM Formation
The mammalian target of rapamycin (mTOR) kinase is a central regulator of many cell processes, including survival, differentiation, and proliferation. It orchestrates cellular responses to external and internal environmental cues. Signaling through the mTOR pathway is an important event for memory formation (13). During each stage of T cell priming, mTOR is activated i.e., TCR/CD28/IL-12. However, inhibiting mTOR in effector CD8 T cells increases the number of memory CD8 T cells in the circulation by increasing the number of effector CD8 T cells that are CD127hiKLRG1−. This suggests that while mTOR is needed early during activation for effector formation, at some point during the effector phase mTOR could be attenuated or turned off in order for effector cells to progress toward memory differentiation.
We recently reported that accumulation of CD8 T cells in the small intestine and FRT is critically dependent on prolonged mTOR signaling (14). We showed that blocking mTOR signaling during the effector phase inhibits the accumulation of effector CD8 T cells in the mucosa thereby limiting TRM formation. This suggests that mTOR controls signals that either direct the migration of CD8 T cells into these barrier tissues or influences their survival. More importantly, because one naive CD8 T cell can give rise to memory in both the SLO and mucosal, our observations indicate that mTOR may regulate the divergence between circulating and resident-memory CD8 T cells. It is also possible that mTOR controls the context in which memory precursors receive signals from cytokines and growth factors. Circulating memory CD8 T cells interact with different stromal and hematopoietic cells than tissue-resident-memory CD8 T cells and this could influence their overall function and survival. For example, IL-15 is an important homeostatic cytokine for memory CD8 T cells, received through a contact-dependent mechanism known as trans-presentation, and for TRM formation (5, 15). Within the memory CD8 T cell populations both IL-15-dependent and IL-15 independent populations have been described. mTOR can be activated by IL-15 and inhibition of mTOR leads to a predominantly IL-15 independent memory population (16, 17).
Many cell types within different tissues produce IL-15 and as a result TRM may receive IL-15 signals more frequently than circulating TEM that may only receive transient IL-15 signals when they circulate through the tissues. While TGF-β induces apoptosis in circulating effector CD8 T cells, TRM generated from effector CD8 T cells rely on TGF-β signals (7, 18). Since mTOR has broad affects on cell physiology and is activated in effector CD8 T cells, mTOR may be central in regulating the unique transcriptional program in TRM. mTOR signaling is mediated by two distinct complexes, mTORC1 and mTORC2 that control responses to environmental cytokine milieus (13). In the absence of mTOR, T cells are unable to respond to cytokines that direct their differentiation (19). The differentiation of naïve CD4 T cells into Th1 and Th2 subsets, requires mTORC1 and mTORC2 signaling, respectively. Loss of mTORC1 signaling in CD4 T cells blocks their ability to upregulate T-bet in the presence of IL-12 (20). IL-12 mediated mTORC1 signaling in CD8 T cells sustains the expression of T-bet and promotes differentiation into effector cells (21). Moreover, inhibiting mTORC1 increases the expression of Eomes and skews memory CD8 T cells toward IL-15 dependence (17). CD4 T cells that lack mTORC2 signaling have diminished responses to IL-4 and IL-13. Less is known about the function of mTORC2 in CD8 T cells. However, given CD4 and CD8 T cells’ shared dependence on the same cytokines or cytokine signaling pathways for their differentiation, the role of mTORC2 in CD8 T cell function will be an important direction for future study.
Are TRM Required for Protection?
A major question is whether TRM positioned at sites of exposure are critical to protect against local re-exposure. The presence of TRM can provide local protection (3). However, circulating memory CD8 T cells can migrate into barrier tissues upon re-challenge and provide protection. However, antigen must first make its way to mucosal draining lymph nodes in order to prime circulating memory CD8 T cells and recruit them to infected tissues. Due to their proximity to infected tissue TRM may be able to respond a pathogen exposure more rapidly than circulating memory CD8 T cells (22). The mucosa is the major route of entry for HIV infection. Within a few hours to days after exposure, HIV can breach the mucosal barrier, infect resting CD4 T cells, and presumably establish latent virus reservoirs (23). In non-human primate models of infection, the latent reservoir is seeded rapidly sometime during the first 3 days of infection creating a big challenge for the immune system (24). The time required for circulating memory CD8 T cells to mount a response may not be quick enough to prevent the establishment of HIV infection. It is now evident that eliminating infected founder cell populations in the area of initial HIV entry is a critical requirement for the immune system to provide protection. Robust TRM responses at the portal of HIV entry may be critical component. Whether TRM can directly kill local infected cells is not explicitly known. The surface area of the mucosa barrier is immense and it is estimated that for every TRM cell there could be tasked to survey as many as ~103 cells (25). Therefore, it is important to know the concentration of TRM that would constitute a critical mass to provide protection. However, recent work has shown that TRM may do more than kill infected cells. TRM can rapidly respond to local challenge and recruit new antigen-specific memory CD8 T cells from the circulation as well as bystander cell populations (26). Moreover, TRM can activate neighboring NK cells and B cells by providing a local source of IL-2, IFN-γ, and TNF-α (27). Collectively, these recent findings suggest that TRM could provide protection not only by killing of infected cells in barrier tissues, but also by taking part in pathogen sensing and initiation of the immune response. Thus it is important to know whether vaccine prime-boost regimens, which can generate large numbers of TRM, will ultimately lead to protection against mucosa-acquired infections such as HIV and HSV.
Manipulating TRM for Clinical Benefit
The observation that upon reactivation TRM are capable of inducing activation of innate cells and even protecting against an antigenically unrelated pathogen may have broader implications for vaccine design (27). It is understood that local priming of CD8 T cells or priming within mucosa draining lymph nodes can generate effector CD8 T cells that can become TRM. Building vaccines that favor priming at these tissue sites and the establishment of long-lived TRM, while challenging, is important, and may include the following strategies. Orally administered vaccines can induce CD8 T cells that accumulate within tissues such as the female reproductive tract and small intestine of the gastrointestinal tract, while attractive the longevity and functional attributes of the memory cells generated from this approach need to be further elucidated (28). Prime-boost strategies using local challenge potentially can increase the number of TRM to a level that can provide protection. Identifying key regulators of TRM formation, as candidate adjuvants to more traditional vaccine strategies, in order to re-direct primed effectors to mucosal tissues to generate increased numbers of TRM. However, the ability of these re-positioned TRM to persist like their counterparts that are generated in situ is still an area of research that warrants further investigation. On the other hand, CD8 TRM cells may also play a central role in tissue destruction in organ-specific autoimmune disorders. The same factors that are important for the generation of TRM may be potential targets for blocking pathogenic CD8 T cell responses in the small intestine of patients with celiac disease. Our findings that low-doses of rapamycin, a pharmacologic mTOR inhibitor, blocked the accumulation of CD8 T cells within the intestinal mucosa suggest the mTOR pathway as a candidate for therapeutic intervention (14). Moreover, we used a model of T cell mediated enterocyte destruction that may have some similarities to celiac disease pathogenesis. Using this model, we demonstrated that rapamycin was capable of blocking the accumulation of CD8 T cells specific for antigen expressed exclusively within the small intestine. In this model, the autoimmunity becomes fatal upon addition of systemic inflammation and the administration of low-dose rapamycin reversed intestinal destruction and enhanced survival. For tumor immunity one hurdle is positioning enough functional CD8 T cells within the tumor milieu. Interestingly, a small population of memory CD8 T cells has been identified in the spleen and lymph nodes that share characteristics of TRM in that they do not re-circulate, and express CD69 (29). It is of significant interest to determine if an equivalent population of TRM populates the tumor and if so how to manipulate these cells to the point where they have a negative impact on tumor growth.
Conflict of Interest Statement
The Associate Editor, Kimberly Sue Schluns, declares that despite having collaborated with author Ryan T. Sowell in the past 2 years, there has been no conflict of interest during the handling of this manuscript. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This research was supported by the National Institutes Health Grants 1R21AI095673-01A1 (Amanda L. Marzo), the Rush Brian Piccolo Cancer Research Fund # 62241 (Amanda L. Marzo), and the Chicago Developmental Center for AIDS Research (D-CFAR), an NIH funded program (P30 AI 082151), which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, and NCCAM) (Amanda L. Marzo).
References
1. Cauley LS, Lefrancois L. Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells. Mucosal Immunol (2013) 6(1):14–23. doi: 10.1038/mi.2012.96
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
2. Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med (2010) 207(3):553–64. doi:10.1084/jem.20090858
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
3. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol (2009) 10(5):524–30. doi:10.1038/ni.1718
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
4. Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev (2013) 255(1):165–81. doi:10.1111/imr.12087
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
5. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol (2013) 13(5):309–20. doi:10.1038/nri3442
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
6. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity (2004) 21(4):527–38. doi:10.1016/j.immuni.2004.08.011
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
7. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol (2013) 14(12):1294–301. doi:10.1038/ni.2744
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
8. Sheridan BS, Pham QM, Lee YT, Cauley LS, Puddington L, Lefrancois L. Oral infection drives a distinct population of intestinal resident memory CD8(+) T cells with enhanced protective function. Immunity (2014) 40(5):747–57. doi:10.1016/j.immuni.2014.03.007
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
9. Masopust D, Vezys V, Wherry EJ, Barber DL, Ahmed R. Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population. J Immunol (2006) 176(4):2079–83. doi:10.4049/jimmunol.176.4.2079
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
10. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrancois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity (2004) 20(5):551–62. doi:10.1016/S1074-7613(04)00103-7
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
11. Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JJ, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity (2013) 38(1):187–97. doi:10.1016/j.immuni.2012.09.020
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
12. Skon CN, Lee JY, Anderson KG, Masopust D, Hogquist KA, Jameson SC. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat Immunol (2013) 14(12):1285–93. doi:10.1038/ni.2745
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
13. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol (2014) 14(7):435–46. doi:10.1038/nri3701
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
14. Sowell RT, Rogozinska M, Nelson CE, Vezys V, Marzo AL. Cutting edge: generation of effector cells that localize to mucosal tissues and form resident memory CD8 T cells is controlled by mTOR. J Immunol (2014) 193(5):2067–71. doi:10.4049/jimmunol.1400074
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
15. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett (2010) 127(2):85–92. doi:10.1016/j.imlet.2009.09.009
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
16. Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol (2014) 15(8):749–57. doi:10.1038/ni.2936
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
17. Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 34(4):541–53. doi:10.1016/j.immuni.2011.04.006
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
18. Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity (2009) 31(1):131–44. doi:10.1016/j.immuni.2009.04.020
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
19. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 30(6):832–44. doi:10.1016/j.immuni.2009.04.014
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
20. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 12(4):295–303. doi:10.1038/ni.2005
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
21. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Immunity (2010) 32(1):67–78. doi:10.1016/j.immuni.2009.10.010
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
22. Masopust D, Picker LJ. Hidden memories: frontline memory T cells and early pathogen interception. J Immunol (2012) 188(12):5811–7. doi:10.4049/jimmunol.1102695
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
23. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature (2010) 464(7286):217–23. doi:10.1038/nature08757
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
24. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature (2014) 512(7512):74–7. doi:10.1038/nature13594
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
25. Casey KA, Fraser KA, Schenkel JM, Moran A, Abt MC, Beura LK, et al. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. J Immunol (2012) 188(10):4866–75. doi:10.4049/jimmunol.1200402
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
26. Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8(+) T cells. Nat Immunol (2013) 14(5):509–13. doi:10.1038/ni.2568
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
27. Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science (2014) 346(6205):98–101. doi:10.1126/science.1254536
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
28. Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, et al. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med (2012) 18(8):1291–6. doi:10.1038/nm.2866
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
29. Schenkel JM, Fraser KA, Masopust D. Cutting edge: resident memory CD8 T cells occupy frontline niches in secondary lymphoid organs. J Immunol (2014) 192(7):2961–4. doi:10.4049/jimmunol.1400003
Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar
Keywords: memory, CD8 T cells, tissue resident, mTOR, mucosa
Citation: Sowell RT and Marzo AL (2015) Resident-memory CD8 T cells and mTOR: generation, protection, and clinical importance. Front. Immunol. 6:38. doi: 10.3389/fimmu.2015.00038
Received: 09 December 2014; Accepted: 20 January 2015;
Published online: 05 February 2015.
Edited by:
Kimberly Sue Schluns, University of Texas MD Anderson Cancer Center, USAReviewed by:
Jonathan Powell, Johns Hopkins University, USAXiao-Ping Zhong, Duke University Medical Center, USA
Copyright: © 2015 Sowell and Marzo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: amanda_marzo@rush.edu